Cell-Based Therapies for EGFR-Positive NSCLC: Today and Tomorrow

Join us for an interactive Facebook Live discussion to learn how immune cells can be engineered to target EGFR+ NSCLC. This webinar features Jill Feldman and Laura Book, members of the EGFR Resisters, and Alexandre Reuben, PhD, from the MD Anderson Cancer Center. Dr. Reuben is a 2023 EGFR Resisters/LUNGevity Foundation grant recipient who works on  engineering T cells to treat several types of lung cancer. The discussion will be moderated by Upal Basu Roy, PhD, MPH, Executive Director of Research at LUNGevity Foundation.